We are analyzing https://link.springer.com/article/10.1007/s00262-011-1002-x.

Title:
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105 | Cancer Immunology, Immunotherapy
Description:
The FDA approval of bevacizumab (Avastin®, Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for anti-angiogenesis tumor therapy, additional targets involved in tumor neovascularization have been identified. One promising target present specifically on tumor vasculature is endoglin (CD105), a member of the TGF-β receptor complex expressed on vascular endothelium and believed to play a role in angiogenesis. Monoclonal antibody therapy and preventive vaccination against CD105 has met with some success in controlling tumor growth. This report describes the in vivo proof-of-concept studies for two novel therapeutic vaccines, Lm-LLO-CD105A and Lm-LLO-CD105B, directed against CD105 as a strategy to target neovascularization of established tumors. Listeria-based vaccines directed against CD105 lead to therapeutic responses against primary and metastatic tumors in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in 20% of mice by week 58 after birth while all control mice developed tumors by week 40. In comparison with previous Listeria-based vaccines targeting tumor vasculature, Lm-LLO-CD105A and Lm-LLO-CD105B demonstrated equivalent or superior efficacy against two transplantable mouse models of breast cancer. Support is provided for epitope spreading to endogenous tumor antigens and reduction in tumor vascularity after vaccination with Listeria-based CD105 vaccines. Reported here, these CD105 therapeutic vaccines are highly effective in stimulating anti-angiogenesis and anti-tumor immune responses leading to therapeutic efficacy against primary and metastatic breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

scholar, google, cancer, pubmed, cas, article, tumor, breast, endoglin, angiogenesis, vaccines, mice, tumors, paterson, res, targeting, vasculature, listeriabased, vascular, growth, mouse, vaccine, cells, human, cell, pan, metastatic, immunol, biol, therapy, target, role, therapeutic, model, endothelial, listeria, bernabeu, solid, mammary, transgenic, privacy, cookies, content, immunotherapy, tsai, seavey, monoclonal, receptor, responses, access,

Topics {✒️}

lm-llo-cd105b demonstrated equivalent anti-endoglin monoclonal antibodies listeria monocytogenes-based vaccines dose-dense doxorubicin/cyclophosphamide chemotherapy tgf-beta-receptor complex month download article/chapter lm-llo-cd105a-vaccinated mice matthew seavey & yvonne paterson listeria-based vaccines directed listeria-based cd105 vaccines tgf-beta superfamily coreceptors anti-angiogenesis tumor therapy stimulate ifn-γ secretion antiangiogenic chimeric anti-endoglin hiv gag-specific cd8 + vascular-specific tgfbeta coreceptor ifn-γ-producing splenocytes algire gh murine s-endoglin isoform cancer immunotherapy targeting listeria-based vaccine listeria-based vaccines myeloid-derived suppressor cells 2/neu-driven breast cancer article cancer immunology stimulating anti-angiogenesis ifn-γ elispot analysis ancillary tgfbeta receptor full article pdf tumor factor responsible vascular endothelial cells endothelial cell markers inhibits tumor growth listeria monocytogenes lm-llo-cd105b human endothelial cells anti-vegf therapy lm-llo-cd105a antigen protein results tumor endothelial cells immune response targeting tumour vasculature privacy choices/manage cookies controlling tumor growth reduced tumor growth cd105 sequence present oral dna vaccine anti-angiogenic effects lm-llo-cd105 lm-llo-e7

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
         description:The FDA approval of bevacizumab (Avastin®, Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for anti-angiogenesis tumor therapy, additional targets involved in tumor neovascularization have been identified. One promising target present specifically on tumor vasculature is endoglin (CD105), a member of the TGF-β receptor complex expressed on vascular endothelium and believed to play a role in angiogenesis. Monoclonal antibody therapy and preventive vaccination against CD105 has met with some success in controlling tumor growth. This report describes the in vivo proof-of-concept studies for two novel therapeutic vaccines, Lm-LLO-CD105A and Lm-LLO-CD105B, directed against CD105 as a strategy to target neovascularization of established tumors. Listeria-based vaccines directed against CD105 lead to therapeutic responses against primary and metastatic tumors in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in 20% of mice by week 58 after birth while all control mice developed tumors by week 40. In comparison with previous Listeria-based vaccines targeting tumor vasculature, Lm-LLO-CD105A and Lm-LLO-CD105B demonstrated equivalent or superior efficacy against two transplantable mouse models of breast cancer. Support is provided for epitope spreading to endogenous tumor antigens and reduction in tumor vascularity after vaccination with Listeria-based CD105 vaccines. Reported here, these CD105 therapeutic vaccines are highly effective in stimulating anti-angiogenesis and anti-tumor immune responses leading to therapeutic efficacy against primary and metastatic breast cancer.
         datePublished:2011-03-23T00:00:00Z
         dateModified:2011-03-23T00:00:00Z
         pageStart:931
         pageEnd:942
         sameAs:https://doi.org/10.1007/s00262-011-1002-x
         keywords:
            Endoglin
            CD105
            Breast cancer
            Vasculature
             Listeria monocytogenes
            Vaccine
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig6_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:60
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Laurence M. Wood
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhen-Kun Pan
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patrick Guirnalda
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Tsai
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthew Seavey
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
                     name:Cephalon, Inc.
                     address:
                        name:Cephalon, Inc., West Chester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yvonne Paterson
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
      description:The FDA approval of bevacizumab (Avastin®, Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for anti-angiogenesis tumor therapy, additional targets involved in tumor neovascularization have been identified. One promising target present specifically on tumor vasculature is endoglin (CD105), a member of the TGF-β receptor complex expressed on vascular endothelium and believed to play a role in angiogenesis. Monoclonal antibody therapy and preventive vaccination against CD105 has met with some success in controlling tumor growth. This report describes the in vivo proof-of-concept studies for two novel therapeutic vaccines, Lm-LLO-CD105A and Lm-LLO-CD105B, directed against CD105 as a strategy to target neovascularization of established tumors. Listeria-based vaccines directed against CD105 lead to therapeutic responses against primary and metastatic tumors in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in 20% of mice by week 58 after birth while all control mice developed tumors by week 40. In comparison with previous Listeria-based vaccines targeting tumor vasculature, Lm-LLO-CD105A and Lm-LLO-CD105B demonstrated equivalent or superior efficacy against two transplantable mouse models of breast cancer. Support is provided for epitope spreading to endogenous tumor antigens and reduction in tumor vascularity after vaccination with Listeria-based CD105 vaccines. Reported here, these CD105 therapeutic vaccines are highly effective in stimulating anti-angiogenesis and anti-tumor immune responses leading to therapeutic efficacy against primary and metastatic breast cancer.
      datePublished:2011-03-23T00:00:00Z
      dateModified:2011-03-23T00:00:00Z
      pageStart:931
      pageEnd:942
      sameAs:https://doi.org/10.1007/s00262-011-1002-x
      keywords:
         Endoglin
         CD105
         Breast cancer
         Vasculature
          Listeria monocytogenes
         Vaccine
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1002-x/MediaObjects/262_2011_1002_Fig6_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:60
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Laurence M. Wood
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhen-Kun Pan
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patrick Guirnalda
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Tsai
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthew Seavey
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
                  name:Cephalon, Inc.
                  address:
                     name:Cephalon, Inc., West Chester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yvonne Paterson
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:60
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:Cephalon, Inc.
      address:
         name:Cephalon, Inc., West Chester, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Laurence M. Wood
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Zhen-Kun Pan
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Patrick Guirnalda
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Peter Tsai
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Matthew Seavey
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
            name:Cephalon, Inc.
            address:
               name:Cephalon, Inc., West Chester, USA
               type:PostalAddress
            type:Organization
      name:Yvonne Paterson
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
      name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
      name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
      name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
      name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
      name:Cephalon, Inc., West Chester, USA
      name:Department of Microbiology, University of Pennsylvania, Philadelphia, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(171)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.22s.

LINK . SPRINGER . COM {}